Lbachir BenMohamed1,2,3, Nelson Osorio4, Arif A Khan1, Ruchi Srivastava1, Lei Huang1, John J Krochmal4, Jairo M Garcia4, Jennifer L Simpson5, Steven L Wechsler4,6,7. 1. a Laboratory of Cellular and Molecular Immunology , Gavin Herbert Eye Institute, University of California Irvine, School of Medicine , Irvine , CA , USA . 2. b Department of Molecular Biology & Biochemistry, School of Medicine , University of California Irvine , Irvine , CA , USA . 3. c School of Medicine, Institute for Immunology, University of California Irvine , Irvine , CA , USA . 4. d Department of Ophthalmology, Virology Research , Gavin Herbert Eye Institute, University of California Irvine, School of Medicine , Irvine , CA , USA . 5. e Department of Ophthalmology , School of Medicine, Gavin Herbert Eye Institute, University of California Irvine , Irvine , CA , USA . 6. f Department of Microbiology and Molecular Genetics , School of Medicine, University of California Irvine , Irvine , CA , USA and. 7. g Center for Virus Research, University of California Irvine , Irvine , CA , USA.
Abstract
PURPOSE: Blinding ocular herpetic disease in humans is due to spontaneous reactivation of herpes simplex virus type 1 (HSV-1) from latency, rather than to primary acute infection. Mice latently infected with HSV-1 undergo little or no in vivo spontaneous reactivation with accompanying virus shedding in tears. HSV-1 reactivation can be induced in latently infected mice by several in vivo procedures, with UV-B-induced reactivation being one commonly used method. In the UV-B model, corneas are scarified (lightly scratched) just prior to ocular infection to increase efficiency of the primary infection and immune serum containing HSV-1 neutralizing antibodies is injected intraperitoneally (i.p.) to increase survival and decrease acute corneal damage. Since scarification can significantly alter host gene transcription in the cornea and in the trigeminal ganglia (TG; the site of HSV-1 latency) and since injection of immune serum likely modulates innate and adaptive herpes immunity, we investigated eliminating both treatments. MATERIAL AND METHODS: Mice were infected with HSV-1 with or without corneal scarification and immune serum. HSV-1 reactivation and recurrent disease were induced by UV-B irradiation. RESULTS: When corneal scarification and immune serum were both eliminated, UV-B irradiation still induced both HSV-1 reactivation, as measured by shedding of reactivated virus in tears and herpetic eye disease, albeit at reduced levels compared to the original procedure. CONCLUSION: Despite the reduced reactivation and disease, avoidance of both corneal scarification and immune serum should improve the clinical relevance of the UV-B mouse model.
PURPOSE: Blinding ocular herpetic disease in humans is due to spontaneous reactivation of herpes simplex virus type 1 (HSV-1) from latency, rather than to primary acute infection. Micelatently infected with HSV-1 undergo little or no in vivo spontaneous reactivation with accompanying virus shedding in tears. HSV-1 reactivation can be induced in latently infectedmice by several in vivo procedures, with UV-B-induced reactivation being one commonly used method. In the UV-B model, corneas are scarified (lightly scratched) just prior to ocular infection to increase efficiency of the primary infection and immune serum containing HSV-1 neutralizing antibodies is injected intraperitoneally (i.p.) to increase survival and decrease acute corneal damage. Since scarification can significantly alter host gene transcription in the cornea and in the trigeminal ganglia (TG; the site of HSV-1 latency) and since injection of immune serum likely modulates innate and adaptive herpes immunity, we investigated eliminating both treatments. MATERIAL AND METHODS:Mice were infected with HSV-1 with or without corneal scarification and immune serum. HSV-1 reactivation and recurrent disease were induced by UV-B irradiation. RESULTS: When corneal scarification and immune serum were both eliminated, UV-B irradiation still induced both HSV-1 reactivation, as measured by shedding of reactivated virus in tears and herpetic eye disease, albeit at reduced levels compared to the original procedure. CONCLUSION: Despite the reduced reactivation and disease, avoidance of both corneal scarification and immune serum should improve the clinical relevance of the UV-B mouse model.
Authors: Guey-Chuen Perng; Barak Maguen; Ling Jin; Kevin R Mott; Nelson Osorio; Susan M Slanina; Ada Yukht; Homayon Ghiasi; Anthony B Nesburn; Melissa Inman; Gail Henderson; Clinton Jones; Steven L Wechsler Journal: J Virol Date: 2002-02 Impact factor: 5.103
Authors: Ruchi Srivastava; Arif A Khan; Doran Spencer; Hawa Vahed; Patricia P Lopes; Nhi Thi Uyen Thai; Christine Wang; Thanh T Pham; Jiawei Huang; Vanessa M Scarfone; Anthony B Nesburn; Steven L Wechsler; Lbachir BenMohamed Journal: J Immunol Date: 2015-01-23 Impact factor: 5.422
Authors: Aziz A Chentoufi; Gargi Dasgupta; Neil D Christensen; Jiafen Hu; Zareen S Choudhury; Arfan Azeem; James V Jester; Anthony B Nesburn; Steven L Wechsler; Lbachir BenMohamed Journal: J Immunol Date: 2010-02-01 Impact factor: 5.422
Authors: Aziz Alami Chentoufi; Nicholas R Binder; Noureddine Berka; Guillaume Durand; Alex Nguyen; Ilham Bettahi; Bernard Maillère; Lbachir BenMohamed Journal: J Virol Date: 2008-09-17 Impact factor: 5.103
Authors: Xavier Dervillez; Huma Qureshi; Aziz A Chentoufi; Arif A Khan; Elizabeth Kritzer; David C Yu; Oscar R Diaz; Chetan Gottimukkala; Mina Kalantari; Maria C Villacres; Vanessa M Scarfone; Denise M McKinney; John Sidney; Alessandro Sette; Anthony B Nesburn; Steven L Wechsler; Lbachir BenMohamed Journal: J Immunol Date: 2013-10-07 Impact factor: 5.422
Authors: Shaohui Wang; Kevin R Mott; Marianne Cilluffo; Casey L Kilpatrick; Shoko Murakami; Alexander V Ljubimov; Konstantin G Kousoulas; Sita Awasthi; Bernhard Luscher; Homayon Ghiasi Journal: J Virol Date: 2018-01-30 Impact factor: 5.103
Authors: Arif A Khan; Ruchi Srivastava; Aziz A Chentoufi; Elizabeth Kritzer; Sravya Chilukuri; Sumit Garg; David C Yu; Hawa Vahed; Lei Huang; Sabrina A Syed; Julie N Furness; Tien T Tran; Nesburn B Anthony; Christine E McLaren; John Sidney; Alessandro Sette; Randolph J Noelle; Lbachir BenMohamed Journal: J Immunol Date: 2017-05-24 Impact factor: 5.422
Authors: Ruchi Srivastava; Arif A Khan; Sumit Garg; Sabrina A Syed; Julie N Furness; Hawa Vahed; Tiffany Pham; Howard T Yu; Anthony B Nesburn; Lbachir BenMohamed Journal: J Virol Date: 2017-01-03 Impact factor: 5.103
Authors: Ruchi Srivastava; Xavier Dervillez; Arif A Khan; Aziz A Chentoufi; Sravya Chilukuri; Nora Shukr; Yasmin Fazli; Nicolas N Ong; Rasha E Afifi; Nelson Osorio; Roger Geertsema; Anthony B Nesburn; Steven L Wechsler; Lbachir BenMohamed Journal: J Virol Date: 2016-03-28 Impact factor: 5.103